The ASPIRE Study

A prospective, multicenter, randomized, double-masked active-controlled study to assess the efficacy and safety of repeat intravitreal injections of foselutoclax (UBX1325) in patients with diabetic macular edema

This study will assess the safety and efficacy of foselutoclax (UBX1325) following repeated intravitreal injections in patients with diabetic macular edema. The medication is intended to remove certain types of aging cells from the body that no longer function properly so that healthy cells can replace the unhealthy cells lining the blood vessels. The leakage of fluid from the blood vessels would thereby be eliminated. The study lasts about nine months.